Mylan, Biocon launch biosimilar of cancer drug Herceptin in Australia

Biotechnology major Biocon and Mylan NV on Thursday launched biosimilar Ogivri, which is used for treatment of certain breast and stomach cancers in Australia. It is a biosimilar of Hoffmann-La Roches Herceptin. Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS), the companies said in a joint statement.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001218 seconds